To qualify, a person must be enrolled in a Medicare Part D plan and meet one of three clinical criteriaassessed at the time you first started GLP-1 therapy, not at the time you apply: BMI of 35 or higher (no additional diagnosis required) BMI of 30 or higher, plus a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension on two or more blood pressure medications, or chronic kidney disease stage 3a or higher BMI of 27 or higher, plus a diagnosis of pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease Your provider submits a prior authorization request attesting you meet the criteriayou dont need to opt in or take any action yourself
In a clinical trial, patients with esophagitis (RE) were randomized into a test or control group, the test group received rabeprazole tablets + Streptococcus lactis MH-02, and the treatment group received rabeprazole tablets + placebo, and the results of the trial showed that patients in the test group experienced earlier symptom relief, significantly lower Gastrointestinal Symptom Rating Scale (GSRS) scores, and a longer mean time to relapse (5)
Aging Cell 19, e13258
Fortified cereals, nutritional yeast, protein shakes, and functional beverages all contribute B12, and energy or wellness products may contain it at doses far above the daily requirement
